Future Oncol. 2015;11(7):1023-1026. Tumor-negative breast cancers misclassified as HER2 negative by IHC (0 or 1+) could therefore be reclassified by FISH, with a remarkable impact on medical ...

aiming to assess HER2 status through immunohistochemical (IHC) staining and fluorescence in-situ hybridization (FISH) analysis. The study found that HER2 protein expression was detected in a ...

They'll probably give you one or more of these tests: The IHC test uses certain antibodies that identify the HER2 protein in a sample of breast cancer tissue. The FISH test uses fluorescent pieces ...

50例患者中，基于中心实验室检测结果，有HER2表达（IHC 1+、2+和3+）的患者为17例（其中仅2例为HER2 IHC 3+），17例为HER2 IHC 0，另外16例患者截至7月15日 ...

for trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ ...

9月13至17日，欧洲肿瘤内科学会（ESMO）年会在西班牙巴塞罗那盛大召开。会上，众多专家学者竞相展示肿瘤学领域的最新研究成果，共同推动肿瘤学科的全球发展。多项来自中国学者的学术成果在本次大会首次亮相，其中，由北京大学肿瘤医院沈琳教授担任主要 ...

The traditional biomarkers that we used to identify who gets treated with her HER2-targeted therapy is really changing. We used to always look at immunohistochemistry as a target. Now we have ...

Both were pooled analysis of two phase I clinical studies of JSKN003 conducted in Australia and China on platinum-resistant ovarian cancer and advanced HER2-positive (IHC 3+) solid tumors.

IMPORTANT SAFETY INFORMATION Unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either: In the metastatic setting ...

Daiichi Sankyo announced that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Enhertu (trastuzumab deruxtecan) for the ...

HER2 mutations involve genetic alterations, while HER2 expression refers to protein overexpression, both impacting NSCLC treatment strategies. Fam-trastuzumab deruxtecan-nxki and ado-trastuzumab ...